Physician profile
May Reyes
NPI 1578624631
$3,455.48
in general payments reported to CMS, 2019-2025
30 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $218 · 2021: $138 · 2022: $372 · 2023: $546 · 2024: $934 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $547.57 | 2021-2025 | Omnipod |
| Amgen INC. | $502.75 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $347.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $285.14 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $242.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.51 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $132.69 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $132.57 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $94.87 | 2019-2022 | |
| Horizon Therapeutics Plc | $89.65 | 2020-2023 | Tepezza |
| Medtronic Minimed, INC. | $89.43 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $79.24 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $68.48 | 2024-2025 | NP Thyroid 60 |
| Radius Health, INC. | $67.11 | 2019-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $59.05 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $52.19 | 2023-2024 | Ilet Bionic Pancreas |
| Sanofi-Aventis U.S. LLC | $49.73 | 2019-2024 | |
| Medtronic, INC. | $48.31 | 2023-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $46.05 | 2021-2024 | Isturisa, Signifor Lar |
| Pfizer INC. | $41.71 | 2024-2025 | |
| Celgene Corporation | $37.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.33 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $34.62 | 2025 | |
| Janssen Biotech, INC. | $32.75 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.65 | 2022-2025 | |
| Ascensia Diabetes Care US INC. | $28.38 | 2023 | |
| Abbvie INC. | $26.32 | 2019-2020 | |
| Becton, Dickinson and Company | $20.06 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.55 | 2024 | Unithroid |
| Glaxosmithkline, LLC. | $13.71 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.